RT Journal Article
SR Electronic
T1 Neoadjuvant Docetaxel/Cyclophosphamide in Triple-negative Breast Cancer: Predictive Value of Class III-β Tubulin and Non-basal Subtype
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 907
OP 912
VO 35
IS 2
A1 KAZUHIRO SHIMADA
A1 TAKASHI ISHIKAWA
A1 KUMIKO KITA
A1 KAZUTAKA NARUI
A1 SADAYOSHI SUGAE
A1 DAISUKE SHIMIZU
A1 MIKIKO TANABE
A1 TAKESHI SASAKI
A1 TAKASHI CHISHIMA
A1 YASUSHI ICHIKAWA
A1 ITARU ENDO
YR 2015
UL http://ar.iiarjournals.org/content/35/2/907.abstract
AB Aim: We aimed to clarify which breast cancer subtypes respond best to docetaxel/cyclophosphamide chemotherapy (TC) as neoadjuvant chemotherapy (NAC). Patients and Methods: We analyzed pathological responses, clinicopathological characteristics and biological markers (estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor-2 (HER-2), Ki-67, p53, topoisomerase IIα, class III β tubulin, cytokeratin 5/6, epidermal growth factor receptor (EGFR)) in specimens from 79 patients who received NAC-TC. Results: Out of 79 patients, 33 (41.8%) achieved quasipathological complete responses (QpCR). Univariate analysis associated negative ER (p<0.001), negative PR (p=0.007), triple-negative subtype (TNBC; p=0.001), high Ki-67 (p=0.022) and low class III β tubulin (p=0.032) with QpCR. Multivariate analyses associated only negative ER (p=0.050) and low class III β tubulin (p=0.028) and only non-basal subtype in TNBC with QpCR. Conclusion: NAC-TC may be especially effective in ER–breast cancer with low class III β tubulin or non-basal TNBC.